Research programme: factor IXa inhibitors - Trigen
Alternative Names: Factor IXa inhibitors research programme - TrigenLatest Information Update: 16 Apr 2010
At a glance
- Originator Trigen Holdings AG
- Class Small molecules
- Mechanism of Action Factor IXa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 21 Feb 2008 This programme is still in active development
- 03 Aug 2005 This programme is still in active development - (BIO-2005)
- 31 May 2005 ProCorde GmbH has merged with Trigen Holdings plc to form Trigen Holdings AG